as IL-6/Stat3, [5] [6] [7] TGF-β/Smad3, [8] [9] [10] Wnt 11, 12 and Notch 13, 14 are implicated in EMT-associated breast cancer metastasis. CD155, also called poliovirus receptor (PVR) or necl-5, harbors conserved amino acids and domain structure similar to the immunoglobulin superfamily. 15 CD155 belongs to the nectin-like molecule family.
Functionally, CD155 interacts with nectin-3 to regulate cell adhesion and migration. 16, 17 CD155 is overexpressed in human cancers. 18 It has been reported that CD155 overexpression promotes cell migration and proliferation. 17, 19, 20 Recently, our group revealed that CD155 was related to cancer cell apoptosis. 21, 22 On the basis of in silico analysis, our present study identified a novel role of CD155 in breast cancer. We found that CD155 was enriched in TNBC and was associated with a mesenchymal phenotype. CD155 knockdown significantly suppressed TNBC cell migration, invasion and metastasis. Therefore, CD155 may be a potential molecular target for TNBC.
| MATERIAL S AND ME THODS

| In silico analysis
Patients negative for expression of ER and PR and amplification of HER2 were considered TNBC patients. The mRNA expression data in tissues were extracted from TCGA and Curtis 23 within Oncomine (https ://www.oncom ine.org/) and GEPIA (http://gepia.cancer-pku. cn/index.html). 24 The correlation of CD155 expression with survival was analyzed by GEPIA and Kaplan-Meier plotter (http://kmplot. com/analy sis/). 25 Expression of CD155 and some other genes in breast cancer cell lines was investigated in GSE12777 26 and Cancer Cell Line Encyclopedia (CCLE) databases (https ://porta ls.broad insti tute.org/ccle). Correlation analysis was performed using the Pearson correlation coefficient. DAVID tool (Version 6.8; https ://david.ncifc rf.gov/) was used to predict pathways 27 and gene ontology (GO).
GO is commonly used to annotate genes from high-throughput genome or transcriptome data. 28 Functional analysis revealed their associated GO molecular processes, biological processes and cellular components. To expand differentially expressed genes (DEGs) into whole transcriptomes, the gene set enrichment analysis (GSEA) analysis was used to test the tendency of all genes in a given pathway for expression profiles. 29 The 311 cases were categorized into a CD155 high expression group and a CD155 low expression group.
GSEA analysis was performed using GSEA v2.0 software (http:// softw are.broad insti tute.org/gsea/index.jsp). Statistical significance was assessed by comparing the enrichment score with the enrichment results generated from 1000 random permutations of the gene set to obtain P-values.
| Cell culture and breast cancer tissues
MDA-MB-231 (ER − PR − HER2 − ) and MCF-7 (ER + PR + HER2 − ) cells were cultured in DMEM (Gibco), and BT549 (ER − PR − HER2 − ), T47D (ER + PR + HER2 − ) and 4T1 (ER − PR − HER2 − ) cells were cultured in RPMI1640 (Gibco). The culture media were supplemented with 10% FBS. All cells were cultured at 37°C in a humidified incubator with 5% CO 2 . The cells were digested using 0.25% trypsin and 0.02 mol/L EDTA in PBS and seeded in 6-well and 12-well plates for the experiments.
Human breast cancer tissues (TNBC 17 cases and non-TNBC 28 cases) and normal breast tissues (15 cases, at least 5 cm away from a tumor) were collected from patients at the First Affiliated Hospital of China Medical University. None of the patients had previously undergone radiotherapy or chemotherapy or any other therapy before the surgery. Approval was obtained for the use of clinical materials for research purposes by the Institutional Research Ethics Committee of China Medical University. All samples were collected and analyzed with the prior written informed consent of the patients. All samples were immediately frozen in liquid nitrogen and stored at −80°C. Then, total RNA and protein from these tissues were isolated. The rest of the tissues were fixed with formalin and embedded in paraffin.
| Lentiviral shRNA transfection
CD155 shRNA lentivirus (shCD155) and control shRNA lentivirus (scramble) were constructed by Obio Technology. The shRNA sequence for shCD155-1 is 5′-CCTAGGCTACATCTTTCTT-3′, for shCD155-2 is 5′-GGGCCAAGTGCACATCATT-3′ and for scramble is 5′-TTCTCCGAACGTGTCACGT-3′. For stable knockdown, shRNA were cloned into pLKD-CMV-Puro-U6-shRNA vector. MDA-MB-231 and 4T1 cells were transfected with 25 MOI of scramble or shCD155 lentivirus. After 48 hours of infection, infected cells were selected by 5 μg/mL puromycin (Sigma) and confirmed as successfully established by using western blot.
| Reagents and antibodies
The rabbit anti-CD155 polyclonal antibody (ab103630) and the mouse anti-α-SMA monoclonal antibody (ab7817) were obtained from Abcam. The rabbit anti-ZO-1 polyclonal antibody (#8193), the rabbit anti-MMP-9 polyclonal antibody (#15561), the rabbit anti-Slug polyclonal antibody (#9585), the rabbit anti-E-cadherin polyclonal antibody (#3195), the rabbit anti-vimentin polyclonal antibody (#5741), the rabbit anti-ZEB1 polyclonal antibody (#3396), the rabbit anti-TGF-β polyclonal antibody (#3711), the rabbit anti-Smad3 polyclonal antibody (#9523), the rabbit anti- 
| Western blot
Total protein was lysed in a modified RIPA buffer containing 1 mmol/L DTT, 1 mmol/L PMSF and complete protease inhibitor cocktail (1 tablet/10 mL; Invitrogen). A total of 30 µg protein was separated on 10% SDS-PAGE gel and transferred to a PVDF membrane. After blocking with 5% skimmed milk, western blots were performed with specific antibodies to detect the corresponding proteins and incubated at 4°C overnight. Then the membrane was washed and incubated with HRP-conjugated secondary antibody (1:5000) for 2 hours at room temperature. To control sampling error, the same blot was also probed for GAPDH as an internal loading control. The specific protein bands were visualized using the enhanced chemiluminescence (ECL) method through the DNR Imaging System. The integral optical density of each band was analyzed using the Image-J software and the ratio of band intensities of target protein over associated control was obtained. Data were expressed as the mean ± SD of at least three independent experiments.
| Immunohistochemistry and image analysis
The tumor tissues were fixed with 4% paraformaldehyde for 72 hours, embedded in paraffin for preparation as H&E or immunostained sections. Briefly, the tissue sections were consecutively deparaffinized in xylene (I, II and III) and rehydrated using a graded series of alcohol (100% alcohol, 95% alcohol, 85% alcohol and 75% alcohol). For H&E, sections were stained with H&E. For immunohistochemistry, endogenous peroxidase was blocked with 3% hydrogen peroxide. Antigen retrieval process was performed in 0.01 mol/L sodium citrate solution (pH 6.0) in a high-pressure steam boiler for 10 minutes. Sections were incubated with first antibody overnight at 4°C. Then, sections were incubated with goat anti-rabbit IgG and streptavidin peroxidase (SP) complex at 37°C for 30 minutes, and developed with the DAB reagent. The sections were observed under an Olympus BX61 microscope. Immunoreactivity was evaluated separately by two experienced pathologists who were blinded to the clinicopathological data of the participants.
Five randomly chosen fields of view were assessed. We used a staining index (SI; values 0-12) with the following formula: SI = staining intensity × staining area, where intensities were scored semiquantitatively as follows: 0 (negative staining), 1 (mild staining), 2 (moderate staining) and 3 (intense staining). The staining area was scored as follows: 0, no staining of cells; 1, <25%; 2, 25%-50%; 3, 50%-75%; and 4, >75%. SI was graded as follows: 0-1, negative expression; 2-3, mild positive expression; 4-8, moderate positive expression and 9-12, strongly positive expression. 30 All three levels were considered positive.
| Immunofluorescence and confocal imaging
Cells were seeded onto adhesion cover slips for 16 hours, fixed with 4% paraformaldehyde in PBS for 15 minutes at 25°C and permeabilized with 0.1% Triton X-100 for 15 minutes. Subsequently, cells were blocked with 1% donkey serum for 30 minutes followed by incubation with specific primary antibodies at 4°C overnight. After washing with PBS three times for 5 minutes, each time, the slides were subjected to fluorescent secondary antibody for 1 hour at room temperature. DAPI was used for nuclear staining. Cells were mounted on glass slides and visualized using a confocal microscope (FV-1000; Olympus).
| Cell Counting Kit-8 assay
Cells were trypsinized and seeded into 96-well plates (1 × 10 3 cells/well). Then, 10 μL Cell Counting Kit-8 (CCK-8; Dojindo
Laboratories) was added and mixed into each well and incubated for 1 hour at 37°C, and absorbance was measured at 450 nm.
Three dependent experiments were repeated. Data were presented as the mean ± SD.
| Colony formation assay
A total of 300 cells/well were trypsinized and cultured on 6-well plates in medium with 10% FBS containing 5% CO 2 for 2 weeks.
Then, the cells were fixed with methanol for 30 minutes and stained with 1% crystal violet for 10 minutes. Colonies of more than 50 cells were counted. All experiments were performed in triplicate. Data were presented as the mean ± SD.
| Flow cytometry for the cell cycle and apoptosis assays
In brief, scramble and CD155 knockdown groups cells were harvested by exposure to trypsin/EDTA and centrifuged at 350 g for 5 minutes. Cell precipitates were washed three times with PBS.
After fixation with 70% ethanol at 4°C overnight, samples were treated with 5 μL RNase A (10 μg/mL) for 1 hour at room temperature, stained with 10 μL propidium iodide (10 μg/mL) on ice for at least 30 minutes at 4°C and analyzed using the FACSCalibur Flow Cytometer (BD Company). All experiments were performed in triplicate. Data were presented as the mean ± SD.
According to the manufacturer's protocol, the apoptotic status was analyzed using an Annexin V-PE/7-AAD Apoptosis Kit (559763; BD Biosciences). Cells were stained and evaluated for apoptosis by flow.
The number of apoptotic cells was analyzed by flow cytometry (BD Biosciences).
| Wound healing assay
Cells were seeded in 12-well culture plates (5 × 10 4 cells/well) and cultured for 24 hours. Then scratches were made on the monolayer cells using a sterile P200 pipette tip to mimic the wound process.
The cells were washed with PBS and were incubated in DMEM containing 2% FBS. Five different zones of each well were chosen and the digital images were captured continuously (×10) from the same field at 0 and 24 hours after scratching. This wound scratch assay was carried out in triplicate. All experiments were performed three times. Data were presented as the mean ± SD. 
| Transwell migration and invasion assays
| Statistical analysis
All experiments were obtained at least in three replicates. In addition, assays producing quantitative data were run in triplicate. SPSS 19.0 software (SPSS) was used. Statistical significance was determined by ANOVA or two-tailed Student's t test. The survival plot was generated by GEPIA and the log-rank test was used for comparison of survival curves. *P < 0.05 was considered to indicate a statistically significant difference.
| RE SULTS
| CD155 is preferentially expressed in triplenegative breast cancer
TCGA and Curtis databases from Oncomine and GEPIA websites were investigated. CD155 mRNA expression was shown to be upregulated in TNBC ( Figure 1A and Figure S1A ). CD155 mRNA expression in human breast cancer specimens and adjacent non-tumorous tissues were thereafter examined by real-time PCR. Consistently, TNBC expressed the highest level of CD155 mRNA ( Figure 1B ). CD155 protein expression was determined by both western blot and immunohistochemistry. These detections confirmed that CD155 protein was overexpressed in TNBC ( Figure 1C-F) . Kaplan-Meier plotter and GEPIA websites were investigated for the correlation of CD155 expression with prognosis. High CD155 expression was associated with shortened overall survival (OS) ( Figure 1G and Figure S1B ). Finally, GO analysis indicated that CD155 might be involved in signaling pathways related to cell adhesion and survival (Figure S1C-E).
| CD155 is associated with mesenchymal phenotype
CD155 expression was determined in several breast cancer cell lines. Mesenchymal/TNBC cell lines such as MDA-MB-231, BT549
and 4T1 expressed higher levels of CD155 than luminal-type cell lines such as MCF7 and T47D (Figure 2A ). The expression pattern of CD155 was similar to that of mesenchymal factors vimentin, Zeb1
and Slug, but differed to that of E-cadherin ( Figure 2B-D) . Using GSEA, we identified a significant enrichment of METASTASIS-EMT high-risk genes in the high CD155 group. (Figure 2E and Figure S2A ). 
| CD155 knockdown induces mesenchymalepithelial transition
CD155 shRNA lentiviruses were used to knockdown CD155 expression in MDA-MB-231 and 4T1 cells ( Figure 3A-D) . The effect of Figure 3E-H) . Immunofluorescent staining further confirmed that CD155 knockdown upregulated E-cadherin expression whereas downregulated vimentin expression ( Figure 3I,J) .
Moreover, CD155 knockdown induced a morphologic transition from mesenchymal-like to epithelial-like in both MDA-MB-231 and 4T1 cells ( Figure S3 ).
| CD155 knockdown suppresses triple-negative breast cancer cell migration, invasion and metastasis
The potential role of CD155 in TNBC metastasis was explored in vitro and in vivo. Wound healing test revealed that CD155 knockdown inhibited migration of both MDA-MB-231 and 4T1 cells ( Figure 4A,B ). Furthermore, a transwell assay showed that CD155 knockdown suppressed cell invasion (Figure 4C,D) . 4T1 cells were injected into mouse tail veins and metastases in the lungs were observed. Consistent with in vitro results, CD155 knockdown significantly blocked lung metastasis of 4T1 cells (Figure 4E-G 
| CD155 cross-talks with IL-6/Stat3 and TGF-β/ Smad3 pathways
To investigate the molecular mechanisms underlying CD155induced EMT and metastasis, GSE12777, CCLE and TCGA were investigated for the association of CD155 with EMT-related signaling pathways. CD155 was shown to be positively correlated with IL-6, TGF-β and Smad3 in these databases ( Figure 5A -C and Figure   S4A -C). GSEA analysis also indicated that CD155 was associated with IL-6 and TGF-β pathways ( Figure S4D ,E). To verify whether CD155 cross-talked with these two pathways, CD155 expression was downregulated in MDA-MB-231 and 4T1 cells by CD155
shRNA transfection. As expected, CD155 knockdown reduced IL-6, TGF-β and Smad3 expression, and inhibited Stat3 phosphorylation ( Figure 5D -G). These findings suggest that CD155 contributes EMT and metastasis by cross-talking with IL-6/Stat3 and TGF-β/Smad3 pathways.
| CD155 knockdown suppresses breast cancer growth and survival
The role of CD155 in TNBC cell growth and survival was finally evaluated. CCK-8 test showed that CD155 knockdown inhibited the viability of MDA-MB-231 and 4T1 cells ( Figure 6A ). Clone formation tests confirmed the inhibitory effect of CD155 knockdown on the growth of these cells ( Figure 6B,C) . Furthermore, flow cytometry indicated that CD155 knockdown enhanced the apoptosis of these cells ( Figure 6D,E) . Consistently, CD155 knockdown increased cleaved caspase-3 expression ( Figure 6F cells with CD155 shRNA transfection harbored more apoptotic cells than those from 4T1 cells with control transfection (Figure S5A,B ).
| D ISCUSS I ON
CD155 is rarely expressed in most normal tissues. However, some human cancers such as colon cancer, pancreatic cancer and lung cancer harbor CD155 overexpression. 21, [31] [32] [33] Our study showed that CD155 was overexpressed in TNBC, but not in other subtypes.
As TNBC patients usually have a poor outcome, we supposed that CD155 overexpression might be associated with an aggressive phenotype. Just as expected, in combination with in silico analysis, we found that CD155 was positively correlated with some mesenchymal markers. Furthermore, CD155 knockdown induced a reverse process of EMT in mesenchymal-like breast cancer cells. These findings indicate that CD155 is involved in the maintenance of breast cancer mesenchymal phenotype.
Mechanistically, EMT is driven by some EMT-TF. Our study revealed that CD155 modulated Zeb1 and Slug, but had no effect on Twist1 and Snail (data not shown). Studies demonstrated that both Zeb1 and Slug played crucial roles in breast cancer cell EMT. 13, [34] [35] [36] Moreover, Zeb1 and Slug were shown to induce TNBC metastasis. 37, 38 Our study further indicated that CD155 knockdown induced mesenchymal-epithelial transition, accompanied by decreased in vitro cell motility and in vivo metastasis. Together, these data suggest that Zeb1 and Slug are involved in the aggressive phenotype of CD155-associated TNBC.
We explored the molecular mechanisms underlying CD155induced EMT and metastasis. The IL-6/Stat3 pathway was identified to cross-talk with CD155 in TNBC cells. IL-6 was involved in TNBC cell growth, survival, migration, metastasis and stemness. [39] [40] [41] [42] [43] As a downstream intracellular molecule of IL-6, Stat3
was also overactivated in TNBC, and associated with the aggressive phenotype. 44, 45 Targeting IL-6/Stat3 was demonstrated to suppress breast cancer growth and metastasis in mouse xenograft models. 39, 44, 46 Consistently, our study showed that CD155 knockdown impaired not only TNBC cell metastasis but also growth and survival. Our study revealed that CD155 knockdown significantly weakened TGF-β expression, indicating that CD155 also cross-talked with TGF-β signaling. In TNBC, TGF-β was shown to induce EMT and metastasis. [47] [48] [49] Smad family members such as Smad2, Smad3
and Smad4 mediated these processes. 48, 50, 51 Our in silico analysis showed that CD155 was positively correlated with TGF-β and Smad3
but not Smad2 and Smad4. CD155 knockdown reduced Smad3 expression, further demonstrating Smad3 to be a downstream effector molecule of CD155 in TNBC.
The mechanism underlying CD155 overexpression in TNBC is unclear. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) were shown to stimulate CD155 expression. 52, 53 In fact, TNBC overproduced ROS, which promoted TNBC cell stemness, chemoresistance and metastasis. 54, 55 Moreover, Ras/MAPK signaling was shown to be involved in CD155 overexpression. 17 Activation of Ras due to the loss of its negative regulators was a common event in TNBC. 56 Suppression of Ras/MAPK signaling inhibited TNBC cell EMT and metastasis. 57 In summary, our study demonstrates for the first time that CD155 is overexpressed in TNBC, which contributes to the aggressive phenotype. Mechanistically, IL-6/Stat3 and TGF-β/Smad3 pathways may be involved in CD155-associated TNBC cell EMT and metastasis.
Suppression of cell motility and metastasis by CD155 knockdown sug-
gests that CD155 is a potential molecular target for TNBC. 
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